Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Henan Taloph Pharmaceutical Stock Co's quarterly Total Liabilities
declined
from Sep. 2025 (¥2,088.81 Mil) to Dec. 2025 (¥1,978.98 Mil) but then
increased
from Dec. 2025 (¥1,978.98 Mil) to Mar. 2026 (¥2,011.07 Mil).
Henan Taloph Pharmaceutical Stock Co's annual Total Liabilities
declined
from Dec. 2023 (¥1,953.47 Mil) to Dec. 2024 (¥1,863.53 Mil) but then
increased
from Dec. 2024 (¥1,863.53 Mil) to Dec. 2025 (¥1,978.98 Mil).
Henan Taloph Pharmaceutical Stock Co Total Liabilities Related Terms
Henan Taloph Pharmaceutical Stock Co Total Liabilities Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Henan Taloph Pharmaceutical Stock Co Total Liabilities Chart
Henan Taloph Pharmaceutical Stock Co Total Liabilities Calculation
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Henan Taloph Pharmaceutical Stock Co (SHSE:600222) has a Total Liabilities of ¥2,011 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Henan Taloph Pharmaceutical Stock Co and its competitors.
Is Henan Taloph Pharmaceutical Stock Co's Total Liabilities too high?
Henan Taloph Pharmaceutical Stock Co's current Total Liabilities is ¥2,011 Mil. Overall, Henan Taloph Pharmaceutical Stock Co has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Henan Taloph Pharmaceutical Stock Co's Total Liabilities compare to ZTS and UTHR?
Henan Taloph Pharmaceutical Stock Co's Total Liabilities of ¥2,011 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Henan Taloph Pharmaceutical Stock Co and its competitors. Henan Taloph Pharmaceutical Stock Co's current Total Liabilities is ¥2,011 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Henan Taloph Pharmaceutical Stock Co stock overvalued right now?
Based on GuruFocus' analysis, Henan Taloph Pharmaceutical Stock Co (SHSE:600222) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥4.91, compared to a current price of ¥7.45 — trading 51.7% above its estimated fair value. The current Total Liabilities is ¥2,011 Mil. Henan Taloph Pharmaceutical Stock Co's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Henan Taloph Pharmaceutical Stock Co (SHSE:600222), the current Total Liabilities is ¥2,011 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Henan Taloph Pharmaceutical Stock Co (SHSE:600222) Overvalued in 2026?
Based on GuruFocus' analysis, Henan Taloph Pharmaceutical Stock Co stock appears to be overvalued.
The current stock price of ¥7.45 is trading 51.7% above its estimated GF Value™ of ¥4.91.
GuruFocus considers Henan Taloph Pharmaceutical Stock Co to be Significantly Overvalued.
Key valuation signals for SHSE:600222:
Total Liabilities: ¥2,011 Mil
GF Value™: ¥4.91 vs. price of ¥7.45 (51.7% above fair value)
No single metric tells the full story. See the SHSE:600222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Henan Taloph Pharmaceutical Stock Co Business Description
Henan Taloph Pharmaceutical Stock Co Ltd is a Chinese company engaged in pharmaceutical manufacturing and pharmaceutical research and development services, including pharmaceutical preparations, Chinese herbal medicine slices, and pharmaceutical research and development services. The company's pharmaceutical preparation business is mainly based on oral Chinese medicine preparations, and its treatment areas cover the respiratory system, cardiovascular and cerebrovascular system, digestive system, and nervous system.
58GF Score
Get the complete analysis for SHSE:600222
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600222 has been successfully added to your 
